

UNITED STAT
United States 1. . . and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO |
|--|---------------|--|-------------------------|-----------------|
| 10/796,947 | 03/10/2004 | OIP Eakomon Amar | 50047/019002 | 4604 |
| 21559 759 | 90 06/28/2006 | (E | EXAMINER | |
| CLARK & ELBING LLP 101 FEDERAL STREET BOSTON, MA 02110 | | AUG 2 2 2006 | JOIKE, MICHELE K | |
| | | | ART UNIT | PAPER NUMBER |
| | | THE PROPERTY OF THE PARTY OF TH | 1636 | |
| | | | DATE MAILED: 06/28/2006 | |

Please find below and/or attached an Office communication concerning this application or proceeding.

| Notice | to | Comply |
|---------------|----|---|
| | •• | ~ · · · · · · · · · · · · · · · · · · · |

| • | 1 '' | |
|---|----------|--|
| 10/796,947 | Am. al | |
| Examiner | Art Unit | |
| Michele K. Joike, Ph.D. | 1636 | |

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

| for | such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s): |
|-----|---|
| Ø | 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). |
| | 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c). |
| | 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). |
| | 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." |
| | 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). |
| | 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). |
| Ø | 7. Other: Sequences are listed with no sequence identifier. See attached. |
| _ | |

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

Technical Assistance......703-287-0200

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Art Unit: 1636

Sequence Compliance

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 because sequences were set forth that lack sequence identifiers. These sequences include the sequences listed in the claims and throughout the specification. Nucleotide sequences with 10 or more nucleotides and amino acid sequences with 4 or more amino acids require sequence identifiers. If the Sequence Listing required for the instant application is identical to that of another application, a letter may be submitted requesting transfer of the previously filed sequence information to the instant application. For a sample letter requesting transfer of sequence information, refer to MPEP § 2422.05. Additionally, it is often convenient to identify sequences in figures by amending the Brief Description of the Drawings section (see MPEP § 2422.02).

Applicants are required to comply with all of the requirements of 37 CFR 1.821 through 1.825. Any response to this office action that fails to meet all of these requirements will be considered non-responsive. The nature of the noncompliance with the requirements of 37 C.F.R. 1.821 through 1.825 did not preclude the continued examination of the application on the merits, the results of which are communicated below.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michele K. Joike, Ph.D. whose telephone number is 571-272-5915. The examiner can normally be reached on M-F, 9:00-6:30.

Application/Control Number: 1. . 96,947

Page 3

Art Unit: 1636

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Irem Yucel, Ph.D. can be reached on 571-272-0781. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Michele K Joike, Ph.D. Examiner
Art Unit 1636

PRIMARY EXAMPLER

ATTORNEY DOCKET NO. 50047/019002

Certificate of Mailing: Date of Deposit: August 18, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Alexis L. Perry

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Amar et al.

Confirmation No.: 4604

Serial No.:

10/796,947

Art Unit:

1636

Filed:

March 10, 2004

Examiner:

Joike, Michele K.

Customer No.:

21559

Title:

NOVEL LITAF BINDING SITE PEPTIDES AND METHODS OF USING

THE SAME

Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

REPLY TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

In reply to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequences that was mailed in connection with the above-captioned application on June 28, 2006, applicant submits the following:

A substitute paper copy of the Sequence Listing;

A substitute copy of the Sequence Listing in computer readable form;

A statement that the contents of the paper and computer readable forms of the

Sequence Listing are the same as one another and contain no new matter; and

A preliminary Amendment directing entry of the Sequence Listing into the specification.

Enclosed is a Petition to extend the period for replying to the Notice for one (1) month, to and including August 28, 2006.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

TODO ARMSTRONF, Ph.D. Reg. No. 54,590

Date: 18 August 2006

For Paul T. Clark

Reg. No. 30,162

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045